YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK (ustekinumab-kfce) is now available to ...

Biocon Biologics has introduced a biosimilar drug, YESINTEK, in the U.S. for treating autoimmune diseases like Crohn's disease, ulcerative colitis, and psoriasis. The launch represents a commitment to ...

MUMBAI:  Biocon Biologics Ltd has announced the US launch of Yesintek  (ustekinumab-kfce), one of the first biosimilars to Janssen's Stelara® to enter the American market. The biosimilar, approved by ...

The Commission held that OCDs bought by Goldman in Biocon Biologics, translating to a 3.8% stake, were not a passive ...

Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

Biologics Ltd (BBL), a subsidiary of Biocon Limited, has secured a major regulatory milestone with the European Commission ...

A number of stocks are set to be in focus during the coming session on Dalal Street, including NTPC, NTPC Green, SBI Card and ...

Biotechnology firm Biocon Ltd on Monday (February 24) said its unit Biocon Biologics announced the US market availability of ...